Clinical pharmacology of slow channel blocking agents.
D000328:Adult; D000368:Aged; D000818:Animals; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D004110:Diltiazem / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000378:metabolism / Q000494:pharmacology / Q000633:toxicity; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004594:Electrophysiology; D006329:Heart Conduction System / Q000187:drug effects; D006801:Humans; D007700:Kinetics; D008875:Middle Aged; D009543:Nifedipine / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology / Q000633:toxicity; D014700:Verapamil / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000378:metabolism / Q000494:pharmacology / Q000633:toxicity
D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine